NUR 611 Final Exam Review
Questions and Answers | 2026 Updated | 100% Correct - Utica College
SECTION 1: PHARMACODYNAMICS & PHARMACOKINETICS (Questions 1–
12)
Q1: A nurse practitioner is reviewing a patient's medication list and notes that the
patient is taking both ketoconazole and simvastatin. Which pharmacokinetic
interaction should the NP be most concerned about?
• A. Decreased renal excretion of simvastatin
• B. Increased hepatic metabolism of simvastatin via CYP3A4 induction
• C. Decreased hepatic metabolism of simvastatin via CYP3A4 inhibition leading to
increased drug levels and myopathy risk
• D. Increased protein binding displacement causing reduced simvastatin efficacy
Correct Answer: C
Rationale: Correct because ketoconazole is a potent CYP3A4 inhibitor that decreases
hepatic metabolism of simvastatin, a CYP3A4 substrate, resulting in elevated simvastatin
levels and increased risk of myopathy and rhabdomyolysis. Per pharmacology principles,
CYP450 inhibitors decrease metabolism of co-administered substrates.
Q2: A 68-year-old patient with heart failure is started on digoxin 0.25 mg daily. The
NP knows that digoxin has a narrow therapeutic index. Which statement best
describes the clinical significance of a narrow therapeutic index?
• A. The drug requires loading doses to reach therapeutic levels quickly
• B. The ratio of toxic dose to effective dose is small, requiring frequent monitoring of
serum drug levels
• C. The drug is primarily metabolized by Phase II conjugation reactions
• D. The drug has a very short half-life requiring multiple daily doses
Correct Answer: B
Rationale: Correct because narrow therapeutic index (TI = LD50/ED50) means the toxic
dose is close to the effective dose, necessitating therapeutic drug monitoring. Standard
,advanced practice requires serum digoxin level monitoring, especially in elderly patients
with decreased renal clearance.
Q3: A patient asks why their oral propranolol dose is higher than the IV dose they
received in the hospital. The NP explains this is primarily due to which
pharmacokinetic phenomenon?
• A. Increased volume of distribution with oral administration
• B. First-pass hepatic metabolism reducing bioavailability of oral propranolol
• C. Increased protein binding with oral formulations
• D. Enhanced renal excretion of oral propranolol
Correct Answer: B
Rationale: Correct because propranolol undergoes extensive first-pass hepatic
metabolism, significantly reducing its bioavailability after oral administration compared
to IV dosing. Guidelines recommend higher oral doses to achieve equivalent systemic
concentrations.
Q4: A drug with a half-life of 6 hours is started at a fixed dose every 6 hours.
Approximately how long will it take to reach steady-state plasma concentration?
• A. 6 hours
• B. 12 hours
• C. 24–30 hours
• D. 48 hours
Correct Answer: C
Rationale: Correct because steady-state plasma concentration is achieved after
approximately 4–5 half-lives. With a 6-hour half-life, 4–5 half-lives equals 24–30 hours.
Per pharmacology principles, this determines appropriate timing for therapeutic drug
monitoring.
Q5: A patient with liver cirrhosis is prescribed a highly lipophilic drug. The NP
anticipates which change in pharmacokinetics?
• A. Decreased volume of distribution due to reduced hepatic blood flow
,• B. Increased volume of distribution due to decreased plasma protein binding and
altered body composition
• C. Increased hepatic metabolism due to enzyme induction from chronic illness
• D. Decreased renal excretion due to reduced glomerular filtration
Correct Answer: B
Rationale: Correct because liver disease decreases albumin synthesis, reducing protein
binding and increasing free drug fraction, while altered body composition in cirrhosis
increases volume of distribution for lipophilic drugs. Standard advanced practice
requires dose adjustments in hepatic impairment.
Q6: Which Phase I metabolic reaction primarily involves the cytochrome P450
enzyme system?
• A. Glucuronidation
• B. Sulfation
• C. Oxidation
• D. Acetylation
Correct Answer: C
Rationale: Correct because Phase I metabolism involves oxidation, reduction, and
hydrolysis, with oxidation primarily mediated by the cytochrome P450 (CYP450) enzyme
system in the liver. Per pharmacology principles, CYP450 enzymes are responsible for
approximately 75% of Phase I reactions.
Q7: A patient on warfarin is started on phenytoin for seizure prophylaxis. The NP
anticipates which change in warfarin levels and why?
• A. Increased warfarin levels due to CYP2C9 inhibition
• B. Decreased warfarin levels due to CYP2C9 induction
• C. Increased warfarin protein binding displacement
• D. Decreased warfarin renal excretion
Correct Answer: B
Rationale: Correct because phenytoin is a potent CYP450 inducer that increases hepatic
metabolism of warfarin (a CYP2C9 substrate), leading to decreased warfarin levels and
, potential loss of anticoagulant effect. Guidelines recommend increased INR monitoring
when enzyme inducers are added.
Q8: Which receptor type is primarily responsible for mediating the effects of
glucocorticoids such as prednisone?
• A. G-protein coupled receptors (GPCR)
• B. Ligand-gated ion channels
• C. Enzyme-linked receptors
• D. Intracellular receptors
Correct Answer: D
Rationale: Correct because glucocorticoids are lipophilic and cross cell membranes to
bind intracellular receptors in the cytoplasm, forming receptor-drug complexes that
translocate to the nucleus to regulate gene transcription. Per pharmacology principles,
steroid hormones act via intracellular receptors.
Q9: A partial agonist is administered to a patient currently taking a full agonist at
the same receptor. What is the expected pharmacodynamic outcome?
• A. Enhanced maximal response due to synergistic receptor activation
• B. Reduced maximal response due to competitive antagonism at the receptor
• C. No change in response because partial agonists do not bind the receptor
• D. Increased potency of the full agonist
Correct Answer: B
Rationale: Correct because a partial agonist has lower intrinsic efficacy than a full
agonist; when both occupy the same receptor population, the partial agonist
competitively reduces the maximal response achievable by the full agonist. Standard
advanced practice requires understanding agonist efficacy differences.
Q10: A patient with renal impairment is prescribed a drug primarily excreted
unchanged by the kidneys. The NP knows that which parameter is most important
to monitor when adjusting the dose?
• A. Alanine aminotransferase (ALT)
• B. Creatinine clearance (CrCl) or estimated glomerular filtration rate (eGFR)
Questions and Answers | 2026 Updated | 100% Correct - Utica College
SECTION 1: PHARMACODYNAMICS & PHARMACOKINETICS (Questions 1–
12)
Q1: A nurse practitioner is reviewing a patient's medication list and notes that the
patient is taking both ketoconazole and simvastatin. Which pharmacokinetic
interaction should the NP be most concerned about?
• A. Decreased renal excretion of simvastatin
• B. Increased hepatic metabolism of simvastatin via CYP3A4 induction
• C. Decreased hepatic metabolism of simvastatin via CYP3A4 inhibition leading to
increased drug levels and myopathy risk
• D. Increased protein binding displacement causing reduced simvastatin efficacy
Correct Answer: C
Rationale: Correct because ketoconazole is a potent CYP3A4 inhibitor that decreases
hepatic metabolism of simvastatin, a CYP3A4 substrate, resulting in elevated simvastatin
levels and increased risk of myopathy and rhabdomyolysis. Per pharmacology principles,
CYP450 inhibitors decrease metabolism of co-administered substrates.
Q2: A 68-year-old patient with heart failure is started on digoxin 0.25 mg daily. The
NP knows that digoxin has a narrow therapeutic index. Which statement best
describes the clinical significance of a narrow therapeutic index?
• A. The drug requires loading doses to reach therapeutic levels quickly
• B. The ratio of toxic dose to effective dose is small, requiring frequent monitoring of
serum drug levels
• C. The drug is primarily metabolized by Phase II conjugation reactions
• D. The drug has a very short half-life requiring multiple daily doses
Correct Answer: B
Rationale: Correct because narrow therapeutic index (TI = LD50/ED50) means the toxic
dose is close to the effective dose, necessitating therapeutic drug monitoring. Standard
,advanced practice requires serum digoxin level monitoring, especially in elderly patients
with decreased renal clearance.
Q3: A patient asks why their oral propranolol dose is higher than the IV dose they
received in the hospital. The NP explains this is primarily due to which
pharmacokinetic phenomenon?
• A. Increased volume of distribution with oral administration
• B. First-pass hepatic metabolism reducing bioavailability of oral propranolol
• C. Increased protein binding with oral formulations
• D. Enhanced renal excretion of oral propranolol
Correct Answer: B
Rationale: Correct because propranolol undergoes extensive first-pass hepatic
metabolism, significantly reducing its bioavailability after oral administration compared
to IV dosing. Guidelines recommend higher oral doses to achieve equivalent systemic
concentrations.
Q4: A drug with a half-life of 6 hours is started at a fixed dose every 6 hours.
Approximately how long will it take to reach steady-state plasma concentration?
• A. 6 hours
• B. 12 hours
• C. 24–30 hours
• D. 48 hours
Correct Answer: C
Rationale: Correct because steady-state plasma concentration is achieved after
approximately 4–5 half-lives. With a 6-hour half-life, 4–5 half-lives equals 24–30 hours.
Per pharmacology principles, this determines appropriate timing for therapeutic drug
monitoring.
Q5: A patient with liver cirrhosis is prescribed a highly lipophilic drug. The NP
anticipates which change in pharmacokinetics?
• A. Decreased volume of distribution due to reduced hepatic blood flow
,• B. Increased volume of distribution due to decreased plasma protein binding and
altered body composition
• C. Increased hepatic metabolism due to enzyme induction from chronic illness
• D. Decreased renal excretion due to reduced glomerular filtration
Correct Answer: B
Rationale: Correct because liver disease decreases albumin synthesis, reducing protein
binding and increasing free drug fraction, while altered body composition in cirrhosis
increases volume of distribution for lipophilic drugs. Standard advanced practice
requires dose adjustments in hepatic impairment.
Q6: Which Phase I metabolic reaction primarily involves the cytochrome P450
enzyme system?
• A. Glucuronidation
• B. Sulfation
• C. Oxidation
• D. Acetylation
Correct Answer: C
Rationale: Correct because Phase I metabolism involves oxidation, reduction, and
hydrolysis, with oxidation primarily mediated by the cytochrome P450 (CYP450) enzyme
system in the liver. Per pharmacology principles, CYP450 enzymes are responsible for
approximately 75% of Phase I reactions.
Q7: A patient on warfarin is started on phenytoin for seizure prophylaxis. The NP
anticipates which change in warfarin levels and why?
• A. Increased warfarin levels due to CYP2C9 inhibition
• B. Decreased warfarin levels due to CYP2C9 induction
• C. Increased warfarin protein binding displacement
• D. Decreased warfarin renal excretion
Correct Answer: B
Rationale: Correct because phenytoin is a potent CYP450 inducer that increases hepatic
metabolism of warfarin (a CYP2C9 substrate), leading to decreased warfarin levels and
, potential loss of anticoagulant effect. Guidelines recommend increased INR monitoring
when enzyme inducers are added.
Q8: Which receptor type is primarily responsible for mediating the effects of
glucocorticoids such as prednisone?
• A. G-protein coupled receptors (GPCR)
• B. Ligand-gated ion channels
• C. Enzyme-linked receptors
• D. Intracellular receptors
Correct Answer: D
Rationale: Correct because glucocorticoids are lipophilic and cross cell membranes to
bind intracellular receptors in the cytoplasm, forming receptor-drug complexes that
translocate to the nucleus to regulate gene transcription. Per pharmacology principles,
steroid hormones act via intracellular receptors.
Q9: A partial agonist is administered to a patient currently taking a full agonist at
the same receptor. What is the expected pharmacodynamic outcome?
• A. Enhanced maximal response due to synergistic receptor activation
• B. Reduced maximal response due to competitive antagonism at the receptor
• C. No change in response because partial agonists do not bind the receptor
• D. Increased potency of the full agonist
Correct Answer: B
Rationale: Correct because a partial agonist has lower intrinsic efficacy than a full
agonist; when both occupy the same receptor population, the partial agonist
competitively reduces the maximal response achievable by the full agonist. Standard
advanced practice requires understanding agonist efficacy differences.
Q10: A patient with renal impairment is prescribed a drug primarily excreted
unchanged by the kidneys. The NP knows that which parameter is most important
to monitor when adjusting the dose?
• A. Alanine aminotransferase (ALT)
• B. Creatinine clearance (CrCl) or estimated glomerular filtration rate (eGFR)
